• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Calcium channel blockers and atherosclerosis.

作者信息

Sowers J R

机构信息

Division of Endocrinology and Hypertension, Wayne State University Medical School, Detroit, MI 48201.

出版信息

Am J Kidney Dis. 1990 Oct;16(4 Suppl 1):3-9.

PMID:2220798
Abstract

Several chemical classes of calcium channel blockers (CCBs) inhibit atherosclerotic lesion formation in rabbit models by reduction of calcium, lipid, and matrix accumulation in the arterial wall. The mechanisms of these antiatherogenic effects are under investigation. Smooth muscle cells and macrophages, which synthesize matrix products and accumulate intracellular lipids, play a central role in lesion formation. Smooth muscle cell hyperplasia, with intracellular and functional changes, is common to both atherosclerosis and hypertension. The antiatherogenic properties of CCBs may be related in part to the protection of arterial cells from calcium overload through inhibition of calcium flux across voltage-regulated ion channels. CCBs may also inhibit cell migration, influence the uptake and catabolism of lipoproteins, alter smooth muscle matrix synthesis, and promote the depletion of intracellular cholesteryl ester stores. It appears that CCBs may inhibit the development of atherosclerotic lesions by two sets of mechanisms: alteration of lipid metabolism in smooth muscle cells and regulation of calcium-initiated or -accelerated intracellular processes.

摘要

相似文献

1
Calcium channel blockers and atherosclerosis.
Am J Kidney Dis. 1990 Oct;16(4 Suppl 1):3-9.
2
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
J Cardiovasc Pharmacol. 1994;24 Suppl 2:S75-84.
3
Calcium channel blockers and atherosclerosis.钙通道阻滞剂与动脉粥样硬化
J Cardiovasc Pharmacol. 1990;16 Suppl 1:S12-5.
4
Calcium, calcium antagonists and experimental atherosclerosis.
Blood Press Suppl. 1996;4:12-5.
5
Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury.钙通道拮抗剂在动脉粥样硬化形成和实验性血管损伤中的保护作用。
Am J Hypertens. 1989 Mar;2(3 Pt 1):205-12. doi: 10.1093/ajh/2.3.205.
6
Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.钙通道阻滞剂对血管蛋白聚糖合成的作用:与动脉粥样硬化的关系。
Vasc Health Risk Manag. 2005;1(3):199-208.
7
[Evaluation of anti-atheromatous properties of calcium channel inhibitors].[钙通道抑制剂的抗动脉粥样硬化特性评估]
Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:161-5.
8
Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.实验性动脉粥样硬化中的钙拮抗剂。伊拉地平的使用依赖性:对动脉粥样硬化动物中增强作用及组织选择性的一种潜在解释。
Am J Hypertens. 1991 Feb;4(2 Pt 2):107S-113S.
9
[Studies on the mechanisms of the antiatherogenic effect of Ca-antagonists].[钙拮抗剂抗动脉粥样硬化作用机制的研究]
Igaku Kenkyu. 1988 Apr;58(2):77-84.
10
Antiperoxidative actions of calcium antagonists and atherogenesis.
J Cardiovasc Pharmacol. 1991;18 Suppl 1:S6-10.